1 / 8

Handling and Use of Information Received from Data Monitoring Committees: Points to Consider

Handling and Use of Information Received from Data Monitoring Committees: Points to Consider October 30th, 2007 Jon Haddad. Agenda. What types of recommendations can be received Appropriate internal recipients Is it ‘actionable’ Some examples for discussion. Types of Recommendations.

risa-yang
Télécharger la présentation

Handling and Use of Information Received from Data Monitoring Committees: Points to Consider

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Handling and Use of Information Received from Data Monitoring Committees: Points to Consider October 30th, 2007 Jon Haddad

  2. Agenda • What types of recommendations can be received • Appropriate internal recipients • Is it ‘actionable’ • Some examples for discussion

  3. Types of Recommendations • Continue without modification • Stop for safety concern • Stop the study for futility • Stop for success • Change sample size • Modify the trial

  4. Internal Recipients • Evaluate potential impact (in advance!) • Look at your organization specifically (Wyeth and Synta are not the same) • Is there another geographic location/operating unit that is sufficiently removed • Is it realistic to expect recommendation to remain undisclosed • What is the ‘real’ need to know? • How does the Sponsor evaluate the recommendation • Is the recommendation automatic based on pre-defined/agreed criteria • Can one do anything with the information once it’s known • Remember, the goal of the DMC is to add independence to risk:benefit evaluation and to avoid comprising the study team with inappropriate information

  5. Internal Recipients, cont. • Define internal procedures • What data will be made available • Who will have access to these data • What protections will be implemented to contain the information within the company • Data Flow and Release procedure • Covers internal and external release of the information • Some companies (e.g., Lilly) have entire departments for release of clinical trial information • Sarbanes/Oxley!

  6. Is it ‘Actionable’? • Continue without modification • Is a press release necessary • Does it tell one anything? Anything ‘material’? Check with your lawyers… • Stop the study • Do you have to accept a DMC recommendation • How do you know if the DMC recommendation is justified • Who will make this assessment • Steering Committee • Internal, non-project staff/committee • Independent agent for sponsor • Input from regulators Check with your lawyers… • Continue with modifications • Assess impact • See above…

  7. Some Examples for Discussion • Continue without modification • Will have to be disclosed to the operational study team • Modify sample size • Clearly gives some indication of how things are going • A precise number may be revealing too much • Pre-define incremental blocks (25-50; 51-100, etc) • Stop for efficacy • How in-depth is the sponsor’s review • How can this be done without team unblinding • If Sponsor decides to keep going, how to protect study from bias going forward

  8. Wrap up • Pre-Consider the potential recommendations that may be received • Decide and document a process for handling recommendations a priori • Take great care in protecting the study team from information that may introduce bias/appearance of bias • Consider carefully the appropriate way to communicate (or not) to the public domain

More Related